Advertisement

Psychotropic Polypharmacy

  • Michelle Cornacchia
  • Priya Chandan
Chapter

Abstract

Polypharmacy is a major issue for individuals with intellectual disability. There have been many proposed definitions of polypharmacy, including using five or more medications. Individuals with intellectual disability are at increased risk for polypharmacy given the presence of multiple co-morbidities such as mental health and neurologic conditions. Commonly prescribed medications for patients with intellectual disability include antipsychotics, anti-epileptics, and antidepressants. Common adverse effects of these medications include sedation, insomnia, nausea, constipation, and weight gain. Importantly, there are strategies that can help reduce polypharmacy and its negative effects, including medication reconciliation tools and processes such as the Systematic Tool to Reduce Inappropriate Prescribing (STRIP).

Keywords

Polypharmacy Psychotropic drugs Intellectual disability 

References

  1. 1.
    Deb S, Farmah BK, Arshad E, Deb T, Roy M, Unwin GL. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder – a systematic review. Res Dev Disabil. 2014;35:711–25.CrossRefGoogle Scholar
  2. 2.
    Haider SI, Ansari Z, Vaughan L, Matters H, Emerson E. Prevalence and factors associated with polypharmacy in Victorian adults with intellectual disability. Res Dev Disabil. 2014;35:3071–80.CrossRefGoogle Scholar
  3. 3.
    Stortz JN, Johanna KL, Cobigo V, Ouellette-Kuntz HMJ, Lunsky Y. Lessons learned from our elders: How to study polypharmacy in populations with intellectual and developmental disabilities. Intellect Dev Disabil. 2014;52:60–77.CrossRefGoogle Scholar
  4. 4.
    O’Dwyer M, Peklar J, McCallion P, McCarron M, Henman MC. Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study. BMJ Open. 2016;6:e010505.CrossRefGoogle Scholar
  5. 5.
    Tonge B, Einfeld S. The trajectory of psychiatric disorders in young people with intellectual disabilities. Aust N Z J Psychiatry. 2000;34:80–4.CrossRefGoogle Scholar
  6. 6.
    Deb S, Unwin G, Deb T. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. J Intellect Disabil Res. 2015;59:11–25.CrossRefGoogle Scholar
  7. 7.
    Scheifes A, Egberts TCG, Stolker JJ, Nijman HLI, Heerdink ER. Structured medication review to improve pharmacotherapy in people with intellectual disability and behavioural problems. J Appl Res Intellect Disabil. 2016;29:346–55.CrossRefGoogle Scholar
  8. 8.
    Lott IT, McGregor M, Engelman L, Touchette P, Tournay A, Sandman C, Walsh D. Longitudinal prescribing patterns for psychoactive medications in community-based individuals with developmental disabilities: Utilization of pharmacy records. J Intellect Disabil Res. 2004;48:563–71.CrossRefGoogle Scholar
  9. 9.
    Eady N, Courtenay K, Strydom A. Pharmacological management of behavioral and psychiatric symptoms in older adults with intellectual disability. Drugs Aging. 2015;32:95–102.CrossRefGoogle Scholar
  10. 10.
    Arvio M, Sillanpaa M. Prevalence, aetiology, and comorbidity of severe and profound intellectual disability (SPID) in Finland. J Intellect Disabil Res. 2004;48:429.Google Scholar
  11. 11.
    Häβler F, Thome J, Reis O. Polypharmacy in the treatment of subjects with intellectual disability. J Neural Transm (Vienna). 2015;122:S93–S100.CrossRefGoogle Scholar
  12. 12.
    van der Heide DC, van der Putten AAJ, van den Berg PB, Taxis K, Vlaskamp C. The documentation of health problems in relation to prescribed medication in people with profound intellectual and multiple disabilities. J Intellect Disabil Res. 2009;53:161–8.CrossRefGoogle Scholar
  13. 13.
    Mahan S, Holloway J, Bamburg JW, Hess JA, Fodstad JC, Matson JL. An examination of psychotropic medication side effects: Does taking a greater number of psychotropic medications from different classes affect presentation of side effects in adults with ID? Res Dev Disabil. 2010;31:1561–9.CrossRefGoogle Scholar
  14. 14.
    Jackson C, Makin S, Marson A, Kerr M. Pharmacological interventions for epilepsy in people with intellectual disabilities. Cochrane Database Syst Rev. 2015;3(9):CD005399.Google Scholar
  15. 15.
    Matson JL, Mahan S. Antipsychotic drug side effects for persons with intellectual disability. Res Dev Disabil. 2010;31:1570–6.CrossRefGoogle Scholar
  16. 16.
    Molina-Ruiz RM, Martín-Carballeda J, Asensio-Moreno I, Montañés-Rada F. A guide to psychopharmacological treatment of patients with intellectual disability in psychiatry. Int J Psychiatry Med. 2017;52:176–89.CrossRefGoogle Scholar
  17. 17.
    McQuire C, Hassiotis A, Harrison B, Pilling S. Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis. BMC Psychiatry. 2015;15:303.  https://doi.org/10.1186/s12888-015-0688-2.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ji NY, Findling RL. Pharmacotherapy for mental health problems in people with intellectual disability. Curr Opin Psychiatry. 2016;29:103–25.CrossRefGoogle Scholar
  19. 19.
    Ayub M, Saeed K, Munshi TA, Naeem F. Clozapine for psychotic disorders in adults with intellectual disabilities. Cochrane Database Syst Rev. 2015;23(9):Cd010625.Google Scholar
  20. 20.
    Rana F, Gormez A, Varghese S. Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities: abridged republication of a Cochrane systematic review. J Psychopharmacol. 2014;28:624–32.CrossRefGoogle Scholar
  21. 21.
    Selph C, Cosca B. Less is more: preventing polypharmacy in individuals with intellectual disabilities. Impact. 2016;29:28–9. Retrieved from https://ici.umn.edu/products/impact/291/291.pdf.Google Scholar
  22. 22.
    Special Olympics International. MedFest medication watch list. Retrieved from http://resources.specialolympics.org/Taxonomy/Health/_Catalog_of_MedFest.aspx.
  23. 23.
    Matson JL, Cervantes PE. Current status of the matson evaluation of drug side effects (MEDS). Res Dev Disabil. 2013;34:1849–53.CrossRefGoogle Scholar
  24. 24.
    Zaal RJ, Ebbers S, Borms M, de Koning B, Mombarg E, Ooms PE, M H. Medication review using a systematic tool to reduce inappropriate prescribing (STRIP) in adults with an intellectual disability: A pilot study. Res Dev Disabil. 2016;55:132–42.CrossRefGoogle Scholar
  25. 25.
    Modi M, McMorris C, Palucka A, Raina P, Lunsky Y. Predictors of specialized inpatient admissions for adults with intellectual disability. Am J Intellect Dev Disabil. 2015;120:46–57.CrossRefGoogle Scholar
  26. 26.
    Kalachnik JE, Sprague RL. The dyskinesia identification system condensed user scale (DISCUS): relability, validity, and a total score cut-off for mentally ill and mentally retarded populations. J Clin Psychiatry. 1993;49:177–89.Google Scholar
  27. 27.
    Trollor JN, Salomon C, Franklin C. Prescribing psychotropic drugs to adults with an intellectual disability. Aust Prescr. 2016;39:126–30.CrossRefGoogle Scholar
  28. 28.
    Deb S, Matthews T, Holt G, Bouras N. Practice guidelines for the assessment and diagnosis of mental health problems in adults with intellectual disability. Res Dev Disabil. 2002;23:234–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Michelle Cornacchia
    • 1
  • Priya Chandan
    • 2
  1. 1.Department of Internal MedicineGeisinger Medical CenterDanvilleUSA
  2. 2.Division of Physical Medicine and Rehabilitation, Department of Neurological SurgeryUniversity of LouisvilleLouisvilleUSA

Personalised recommendations